Fenty Beauty South Africa,
Tanner Pearson Instagram,
Scholastic Teaching Resources Grade 5,
Emma Forbes Harvard,
El Toro Brownsburg Menu,
Andrew Luck Draft Profile,
Universal Leaf Email Address,
Hermès Tag On Scarf,
Frank Winfield Woolworth Net Worth,
The Shapes Song,
How To Get Chile Passport,
Ryan Ellis Music,
Igotcha Gps Installation,
Sephora Brush Set Uk,
Giovanni Caforio Bio,
Bnl Triple Platinum,
Vans - Youtube,
Starbucks Design Strategy,
Safety Pin Brooch,
Convict Life In Australia,
Bernadette Caulfield Age,
Echo Show Review,
Barbados Racing Calendar 2020,
Ottawa Rough Riders Logo History,
Prezzo Menu Pdf,
Afl Fixture 2020 Broadcast Guide,
Hermes Evelyne Tpm Price 2019,
Kwon Alexander Finds Out Brother Died,
Labor Organization Crossword Clue,
Mark Bergmann Professor,
Bobby Murphy Net Worth,
Chernobyl New Safe Confinement Inside,
Giraffe Brunswick Menu,
Jcpenney Coupon Giveaway 2020,
Mixed-ish Full Episode,
Geelong Theme Song (Lyrics),
The company will begin investigating the drug candidate on adult patients with severe SCD. The stock had previously closed at $20.96. If continued trials prove safe and effective, this drug could potentially be a game-changer, but it could also face competition from other gene editing companies.CRISPR Therapeutics is also working on its own portfolio of chimeric antigen receptor T-cell (CAR-T) therapies based on gene editing technology. Valeo Financial Advisors LLC grew its stake in Intellia Therapeutics by 1,078.0% in the second quarter. FDx Advisors Inc. bought a new position in Intellia Therapeutics in the second quarter valued at approximately $254,000. ET by Tomi Kilgore Intellia Therapeutics upgraded to … The sector with the worst average Zacks Rank (16 out of 16) would place in the bottom 1%.This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein.
The stock traded as low as $20.92 and last traded at $20.23, approximately 16,831 shares traded hands during mid-day trading. Get the latest Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Shares of Intellia Therapeutics Inc (NASDAQ:NTLA) were down 3.5% during mid-day trading on Wednesday . CRISPR recently enlarged its cash stash to $900 million with a milestone payment it received from the Vertex collaboration in April, and it is eligible to receive up to $800 million in additional milestone payments from these programs.Stock Advisor launched in February of 2002. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.Zacks Earnings ESP (Expected Surprise Prediction) looks to find companies that have recently seen positive earnings estimate revision activity.
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 4%Summit Hotel Properties (NYSE:INN) Shares Up 0.4%Several hedge funds have recently modified their holdings of NTLA. The company currently has an average rating of “Buy” and an average price target of $28.25. Finally, Bank of Montreal Can raised its position in Intellia Therapeutics by 32.8% during the fourth quarter. Exchange Traded Concepts LLC now owns 14,042 shares of the company’s stock valued at $295,000 after purchasing an additional 6,516 shares in the last quarter. The stock had previously closed at $20.96. This value reflects … Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. Institutional investors own 90.46% of the company’s stock.Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria.A number of hedge funds have recently bought and sold shares of the business.
Each of the company logos represented herein are trademarks of Verizon Media; Microsoft Corporation; Nasdaq, Inc.; Dow Jones & Company; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. The company expects to report data on its CTX110 trial at the end of 2020.CRISPR Therapeutics has a portfolio of therapeutic programs in various diseases including hemoglobinopathies, oncology, regenerative medicine, and rare diseases.
Wedbush increased their price objective on Intellia Therapeutics from $16.00 to $20.00 and gave the company a “neutral” rating in a report on Monday, June 1st. Hedge funds and other institutional investors own 90.46% of the company’s stock.Sprott Physical Platinum and Palladium (NYSEARCA:SPPP) Shares Up 2%General Moly (NYSEAMERICAN:GMO) Trading Up 20.7% The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season.At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. As mentioned earlier, the SCD market offers a massive opportunity if Intellia achieves its milestones successfully. It has nine product candidates total, with four promising studies in the clinical testing phase. CRISPR Therapeutics commands a market valuation of $3.8 billion, more than four times the $900.2 million market cap of Intellia. The hemoglobinopathy market is expected to reach $12.6 billion by 2026 and to expand at a compound annual growth rate (CAGR) of 10.2%. See rankings and related performance below.The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries.